1Q22 Business Results

Key Business Performance Herzuma ✓ Securing profitability by strategic participation in tenders as a leading HerceptinⓇ biosimilar in Europe ✓ Surpassed the market share of the original in Japan & Increased demands in LATAM boosted sales growth Market share of HerzumaⓇ in Europe 1% 10% Market share of HerzumaⓇ in Japan 19% 16% 15% 15% 14% 14% 25% 19.08 approval of 3-weekly regimen 12% 2% 0% 53% 50% 51% 46% 44% 39% 35% 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 21.2Q 4Q 19.2Q 3Q 4Q 20.1Q 2Q 3Q 4Q 21.1Q 2Q 3Q 4Q 40 Herzuma® HerceptinⓇ E Biosimilar F Biosimilar G Biosimilar Note: market share is based on volume Source: IQVIA Herzuma® Note: market share is based on volume Source: IQVIA Herceptin® Investor Relations 2022 10

View entire presentation